Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-230X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study ; volume:21 ; number:1 ; day:22 ; month:1 ; year:2021 ; pages:1-10 ; date:12.2021
BMC gastroenterology ; 21, Heft 1 (22.1.2021), 1-10, 12.2021
- Urheber
-
Mühl, Laura
Becker, Emily
Müller, Tanja M.
Atreya, Raja
Atreya, Imke
Neurath, Markus F.
Zundler, Sebastian
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12876-021-01604-z
- URN
-
urn:nbn:de:101:1-2021031418154216976080
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:30 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mühl, Laura
- Becker, Emily
- Müller, Tanja M.
- Atreya, Raja
- Atreya, Imke
- Neurath, Markus F.
- Zundler, Sebastian
- SpringerLink (Online service)
Ähnliche Objekte (12)
Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF?
Predicting Therapeutic Response by in vivo Molecular Imaging in Inflammatory Bowel Diseases
Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study
Endoscopy as a Diagnostic Tool for Personalized Therapy in IBD: Prediction of Response to Biological Therapy
Oligonucleotides—A Novel Promising Therapeutic Option for IBD
Role of the IL23/IL17 Pathway in Crohn’s Disease
Endoscopic Therapy in Inflammatory Bowel Diseases
Quantitative contrast-enhanced ultrasound for monitoring vedolizumab therapy in inflammatory bowel disease patients: a pilot study
Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases
Limited Dose-Dependent Effects of Vedolizumab on Various Leukocyte Subsets
Smad7 Antisense Oligonucleotide-Based Therapy in Crohn's Disease: Is it Time to Re-Evaluate?
Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF?
Predicting Therapeutic Response by in vivo Molecular Imaging in Inflammatory Bowel Diseases
Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study
Endoscopy as a Diagnostic Tool for Personalized Therapy in IBD: Prediction of Response to Biological Therapy
Oligonucleotides—A Novel Promising Therapeutic Option for IBD
Role of the IL23/IL17 Pathway in Crohn’s Disease
Endoscopic Therapy in Inflammatory Bowel Diseases
Quantitative contrast-enhanced ultrasound for monitoring vedolizumab therapy in inflammatory bowel disease patients: a pilot study
Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases
Limited Dose-Dependent Effects of Vedolizumab on Various Leukocyte Subsets
Smad7 Antisense Oligonucleotide-Based Therapy in Crohn's Disease: Is it Time to Re-Evaluate?
Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF?
Predicting Therapeutic Response by in vivo Molecular Imaging in Inflammatory Bowel Diseases
Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study
Endoscopy as a Diagnostic Tool for Personalized Therapy in IBD: Prediction of Response to Biological Therapy
Oligonucleotides—A Novel Promising Therapeutic Option for IBD
Role of the IL23/IL17 Pathway in Crohn’s Disease
Endoscopic Therapy in Inflammatory Bowel Diseases
Quantitative contrast-enhanced ultrasound for monitoring vedolizumab therapy in inflammatory bowel disease patients: a pilot study
Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases
Limited Dose-Dependent Effects of Vedolizumab on Various Leukocyte Subsets
Smad7 Antisense Oligonucleotide-Based Therapy in Crohn's Disease: Is it Time to Re-Evaluate?